Detail Study on Medical Carts Market is Projected to Grow Magnificent CAGR till 2023

 

Market Highlights

The growing acceptance of medical carts accustomed by its technical advances is one of the major trends witnessed in the global medical computer carts market over the forecast period.

According to world health organization, musculoskeletal conditions are the second largest contributor to disability globally. Musculoskeletal conditions include conditions that affect joints (psoriatic arthritis, gout, osteoarthritis, rheumatoid arthritis), bones (osteoporosis, osteopenia and associated fragility fractures), and muscles (sarcopenia).

Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as high cost of advanced medical carts in developing countries, is likely to curb the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7436 

Segmentation

The global medical carts market is segmented based on product type, type, material type, and end-users.

The medical carts market, by product type, the market is segmented into mobile computing carts, medical storage columns, wall-mounted workstations, medication carts, and others.

Based on type, the market is segmented into computer medical cart, procedure cart, emergency cart, anaesthesia cart, and others.

Based on material type, the market is segmented into metal type, plastic type, and others.

 Based on end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, and others.

Regional Analysis

The Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians. It is currently exhibiting a highly lucrative growth rate due to an increased use of medical carts for various applications. 

The European region is the second largest medical carts market over the forecast period due to high acceptance of medical carts in developing countries along with the rising incidence of chronic diseases are also accountable for the growth of the medical carts market.   

The Asia Pacific region is likely to develop at the uppermost CAGR for the medical carts market in the years to come. Moreover, the rising patient safety at the hospitals and at community level are expected to influence the market in a positive way.

The Middle East and Africa accounts for the least market share due to low per capita income and lack of availability of well-trained healthcare professionals. 

Key Players

Some of the key players in the global medical carts market are ITD GmbH (Germany), Advantech Co. (Taiwan) Ltd, Harloff Manufacturing Co. (US), AFC Industries (US), Chang Gung Medical Technology Co. (Taiwan), Omnicell Inc. (US), Midmark Corporation (US), The Bergmann Group (US), Capsa Healthcare (US), Jaco Inc (US), Waterloo Healthcare (US), Ergotron Inc (US) and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/medical-carts-market-7436 

Future Growth of Advanced Wound Therapy Devices Market is Expected to Grow Healthy CAGR till 2023

 

Overview:

The global advanced wound care therapy devices market is anticipated to touch a value of USD 2,804.53 million by 2023, asserts Market Research Future (MRFR). The market can showcase 6.70% CAGR from 2018 to 2023 (forecast period).

Increasing incidence of diabetes is the primary driver of the market. Patients with diabetes have a slower healing rate and poor blood circulation which can negatively affect the immunity system. According to the Centers for Disease Control & Prevention (CDC), nearly 30.3 million in the U.S. suffer from diabetes. The advanced wound therapy devices market can expand by capitalizing on this trend and offering precise solutions.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7421 

The growing numbers of the geriatric populace will be highly beneficial to the market. This is buttressed by the estimation by the World Health Organization (WHO) which pegs the elderly populace at 1.2 billion by 2025. Furthermore, development of novel products and rapid approval by regulatory bodies is projected to propel the advanced wound therapy devices market. For instance, ConvaTec got approval for its negative pressure wound therapy (NPWT) system by the U.S. FDA in 2018. The hydrofiber gels in the system lock the exudates and bacteria and offer a separate channel for the them to flow away from the wounded region.

Segmentation Analysis: 

The advanced wound therapy devices market is segmented by type and end-user.

By type, negative pressure wound therapy systems accounted for 42.9% share in 2017, followed by pressure relief devices (28.2%), hyperbaric oxygen equipment (15.2%), electric stimulation devices (7.9%), and others (5.8%). Negative pressure wound therapy systems can attain revenue close to USD 1,217.41 million by 2023 at 6.91% CAGR over the forecast period. But pressure relief devices are projected to experience the highest CAGR of 7.03% during the assessment period to accrue close to USD 805.35 million by 2023.

Among end-users, hospitals & clinics accounted for 73.7% share in 2017, followed by home care settings (14.5%), and others (11.8%). Hospitals & clinics can register close to 6.95% CAGR during the forecast period to generate close to USD 2,095.66 million by 2023. On the other hand, the home care settings segment is expected to exhibit 6.78% CAGR to touch a size of USD 408.50 million by the end of the forecast period.

Regional Analysis:

Region-wise, the advanced wound therapy devices market is segmented into Europe, Asia Pacific (APAC), Americas, and the Middle East & Africa (MEA).

The Americas are anticipated to reign as the leading region of the market owing to a mix of attractive reimbursement schemes, numerous treatment options, and prevalence of diabetes and chronic wounds. The region can accumulate close to USD 993.07 million by 2023 at 6.11% CAGR over the forecast period.

The European region is touted to register a notable growth rate owing to awareness of chronic wounds, rise in government initiatives, and awareness among healthcare providers. Presence of reputed companies such as Lohmann & Rauscher and technological advances of products can drive the regional advanced wound therapy devices market growth. The region can accrue close to USD 924.85 million by 2023 at 7.02% CAGR over the forecast period.

The APAC region is expected to be extremely lucrative for the advanced wound therapy devices market. This can be credited to high number of burn injury cases and awareness of NPWT devices. It can attain a size of USD 676.27 million by 2023 at 7.16% CAGR over the assessment period.

Competitive Analysis:

Notable player names in the advanced wound therapy devices market are Cardinal Health (U.S.), ConvaTec Inc. (U.K.), Smith & Nephew plc (U.K.), Triage Meditech Pvt. Ltd. (India), Medela AG (Switzerland), Sechrist (U.S.), Mölnlycke Health Care AB (Sweden), B. Braun Melsungen AG (Germany), DeRoyal Industries, Inc. (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), Perry Baromedical (U.S.), and KCI Licensing, Inc. (U.S.).

Browse Complete Report @ https://www.marketresearchfuture.com/reports/advanced-wound-therapy-devices-market-7421

Dental Practice Management Software Market – A market with high CAGR and return on investment by 2023

 Market Research Future (MRFR)’s study projects healthy growth for the global dental practice management software market in the forthcoming years.  The latest developments in oral healthcare technologies have paved the way for the adoption of software all across the world. Additionally, the increasing awareness about oral healthcare coupled with rising dental healthcare expenditure is expected to favor the expansion of the market over the next couple of years.

The exponential geriatric population has opened new avenues of growth opportunities for service providers in the oral healthcare industry. According to data published by World Population Prospects: the 2017 Revision, the population of older people, over 60 years, is expected to get doubled by 2050. It is anticipated to augment the oral healthcare industry. This, in turn, is prognosticated to accelerate the adoption of dental practice management software in the industry.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6507

The growth trajectory of the market is guided by the rising technological advancements in the dental healthcare industry and its large-scale adoption. The need for better technology for enhanced efficiency has intensified in the dental healthcare industry. The large-scale prevalence of dental disorders owing to the changing lifestyle and food habits is another major factor responsible for complementing the growth of the global market. It is likely to accelerate the revenue creation for the market participants in the foreseeable future.

The market scenario looks attractive at present and is forecasted to remain highly lucrative in the coming years. Furthermore, investments are likely to flow towards the global dental practice management software market over the next couple of years. Nevertheless, lack of skilled personnel remains an impediment to the market proliferation.

Companies Covered

Some of the global dental practice management software market companies are Curve Dental, Practice Web, Henry Schein, NextGen Healthcare Information Systems, LLC., Carestream Dental, DentiMax, Patterson Dental, Allscripts Healthcare Solutions, and Dovetail Dental Software.

Report Overview

This MRFR report presents a comprehensive analysis of the key market trends and an outlook for product segments and major regions highlighting the growth trajectories during the assessment period. It reveals that dental practice management software finds application in invoicing/billing, charting, patient management, insurance management, and others. A detailed analysis is also included based on on-premise, web-based, and cloud-based deployment mode. The regional analysis of the market spans across North America, Europe, Asia Pacific, and the Rest of the World.

Report Coverage

Historical market trends, forecast, key player’s market share analysis, market dynamics, and market factor analysis which covers supply chain and Porter’s five forces analysis of the market. The report also encompasses market value by region as well as by segmentation, and country-level analysis for each market segment.

Research Methodology

MRFR leverages its industry expertise for delivering actionable insights into the markets. An in-depth study of the market elements influencing the forecast is performed for drawing insightful conclusions. The information presented in our reports are backed by data sourced through extensive primary and secondary research. Top-down and bottom-up approaches are employed for authenticating the accuracy of the market size and revenue estimation. A multi-layer verification process further affirms the credibility of the quantitative and qualitative data available in our reports.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/dental-practice-management-software-market-6507

Costochondritis Market | Worldwide Top key Players Profile Analysis | Forecast till 2023

 Market Scenario

Costochondritis is an inflammatory condition of the cartilage which connects a rib to the sternum. It is sometimes called chest wall pain, costosternal chondrodynia, or costosternal syndrome. The pain caused by costochondritis might be similar to that of a heart attack. Costochondritis is a common cause of chest pain in adolescents and children. It is estimated that the global costochondritis treatment market is expected to register an increasing CAGR during the forecast period from 2018 to 2023.

The factors causing costochondritis can be injury in chest, physical strain, osteoarthritis, arthritis, ankylosing spondylitis, and tumors (cancerous or noncancerous).  Also, costochondritis may be caused by bacterial, viral, and fungal infections. According to the Centers for Disease Control and Prevention, August 2018, it has been estimated that 22.7% of the US adults had some form of rheumatoid arthritis from 2013 to 2015. The growing percentage of arthritis patients would support the costochondritis market positively.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6500

However, factors such as the high cost of surgical procedures, expensive treatments, and side effects related to treatments are expected to restrict the market growth during the forecast period.

Segmentation

The global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user. The costochondritis market, by diagnosis, is categorized into various tests. The test is sub-segmented into echocardiogram, electrocardiogram, stress tests, cardiac catheterization, chest X-ray, cardiac MRI, and CT scan. On the basis of treatment, the market is segmented into medications, therapy, and surgery.

The medications treatment is further sub-segmented into nonsteroidal anti-inflammatory drugs, narcotics, antidepressants, and anti-seizure drugs. Therapy is sub-segmented into stretching exercises and nerve stimulation. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

On the basis of region, the global costochondritis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the UAE, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players in the global costochondritis market are KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others.

Regional Market Summary

It is estimated that North America dominated the global costochondritis market owing to the increased cardiac diseases, increasing prevalence of syphilis, innovations in clinical practice, heart research, and access to heart treatments in this region. According to the Centers for Disease Control and Prevention (CDC), September 2017, the total syphilis cases reported to CDC increased by 17.8% during 2015 to 2016. The increase in the cases of syphilis supports the market growth in this region.

Europe stood the second largest in the costochondritis market owing to increasing hypertension and heart attack cases. According to the Public Health England in January 2017,

high blood pressure is the third highest risk factor for disease in the UK. It affected one in four adults and around 12.5 million people in 2015 in England. This number is expected to increase during the forecast period.  Such a high incidence of high blood pressure supports the growth of costochondritis in this region.

Asia-Pacific was estimated to be the fastest growing region for the global costochondritis market in 2017. The market is expected to witness growth owing to the rising prevalence of heart problems, car accidents, and changing lifestyle.

The Middle East and Africa holds the least share in the global costochondritis market due to the presence of low health expenditure, low awareness of innovative technology, and economically diverse countries. However, the market is expected to witness growth due to increasing cardiac care programs and an increase in investments in research and development in the Middle East.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/costochondritis-market-6500

Future Growth of Blood Group Typing Market is Expected to Grow Healthy CAGR till 2023

 Market Scenario

Global blood group typing market size is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 10.2% over the assessment period. Blood group typing is a method of determining the type of blood group of an individual.  Blood group typing is a mandatory requirement before blood transfusion to examine the compatibility between the donor and recipient blood group. Additionally, blood typing is of significant importance in pregnant women in cases where the father of the baby has RhD positive blood group and the mother has RhD negative blood group. The global blood group typing has witnessed significant growth owing to the technological advancements in blood group detections methods. Technological advancements such as quantum dots (QDs) and magnetic beads in assays improve identification and thus enhance the clinical safety of the blood transfusion.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6410

The factors such as growing demand for blood products need for blood grouping during prenatal testing, increasing number of road incidents, growing number of road accidents and trauma cases which requires a blood transfusion, the rise in blood donations, and growing usage of blood typing in the forensic sciences. According to The American National Red Cross, about 21 million blood components are transfused each year in the US. Following the same source, each year, an estimated 6.8 million people in the US donate blood.

However, the stringent regulatory requirements for blood transfusion may hinder the growth of the global blood group typing market.

Segmentation

The global blood group typing market has been segmented into technique, test type, product and service, and end user.

The market, by technique, has been segmented into PCR-based and microarray techniques, assay-based techniques, massively parallel sequencing, and others.

The market, by test type, has been segmented into antibody screening, HLA typing, ABO blood tests, cross-matching tests, and antigen typing.

The global market, on the basis of product and service, has been segmented into consumables, instruments, and services. The consumables segment has been segmented into antisera reagents, red blood cells reagents, anti-human globulin reagents, and blood bank saline.

On the basis of end user, the market has been segmented into hospitals, blood banks, clinical laboratories, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The blood group typing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European blood group typing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The blood group typing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The blood group typing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Bio-Rad Laboratories, Inc., Grifols International, S. A., Beckman Coulter, Immucor, Inc., Ortho Clinical Diagnostics, Inc., Quotient, Ltd., Novacyt Group, Bag Healthcare GmbH, Rapid Labs, AXO Science, Agena Biosciences, Inc., Day Medical SA, and Merck KGaA are some prominent player in the market.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/blood-group-typing-market-6410

Future Growth of Biopreservation Market is Expected to Grow Healthy CAGR till 2023

 Market Scenario

The global biopreservation market size is expected to grow during the forecast period (2018–2023) at a CAGR ~11.2%.

Biopreservation is a use of natural flora and its antibacterial products to preserve biological material. Biopreservation is playing an important role in healthcare and food industry to preserve the biological material or food product for a long time. The increasing expenditure on healthcare, growing demand for stem cell preservation and awareness about its use with regards to treatment of diseases are expected to drive the growth of the market. Moreover, increasing awareness about personalized medicines and its applications are contributing to the growth of the market. According to the US Food and Drug Administration (FDA), The department has approved 16 personalized medicines in the year 2017, which accounts for 20% of total drug approvals.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6407

The rising high price of biopreservation instruments and its maintenance, stability issues related to the specimen and lack of skilled personnel for handling the biopreservation process may hamper the growth of the market during the assessment period.

Segmentation

The global biopreservation market has been segmented on the basis of product, biospecimen, and application.

On the basis of product, the market has been classified as media and equipment. The media subsegment has been further divided into nutrient media, sera, and growth factors and supplements. The equipment segment has been further divided into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems segment has been further classified as freezers, cryogenic storage systems, thawing equipment, and refrigerators. The biospecimen segment has been divided into human tissue samples, organs, stem cells, and other biospecimens.

The market, by source, has been segmented into regenerative medicine, biobanking, and drug discovery. On basis of regenerative medicine, the market has been divided into cell therapy, gene therapy, and others. Biobanking segment includes human egg, human sperm, and veterinary IVF.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biopreservation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European biopreservation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The biopreservation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biopreservation market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global biopreservation market owing to the adoption of advanced technology, increasing spending on healthcare R&D, the presence of a well-established healthcare system, and increasing in-house sample storage in hospitals and research institutes. Moreover, presence and recent merger and acquisition activities by market players in the region are contributing to the growth of the market.  For instance, in 2017, Cesca Therapeutics Inc. has acquired Sacramento’s SynGen Inc. for USD 1 million with this acquisition company has managed to add cell separation and cord blood processing products in their portfolio.

The European market is expected to be the second-largest biopreservation market. The market growth in this region can be attributed to the increasing number of births and with-it continuous increase in demand for umbilical cord preservation. According to the European Commission, in the year 2016 more than 5.1 million babies were born in Europe.  Moreover, a growing number of sperm and egg banks is contributing to the growth of the market in this region.

Asia-Pacific is expected to be the fastest-growing biopreservation market during the forecast period owing to the increasing population in the region, increasing awareness about stem cell preservation and continuous development in the healthcare sector due to government funding.

The market in the Middle East & Africa is expected to account for the smallest share of the global biopreservation market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global biopreservation market are Thermo Fisher Scientific, Inc, VWR International, LLC., CUSTOM BIOGENIC SYSTEMS., BioLifeSolutions Inc., BioCision., Sigma-Aldrich Co., QIAGEN, Lifeline Scientific, Cesca Therapeutics Inc., Core Dynamics, Ltd., Princeton CryoTech, Biomatrica, Inc., Panasonic Biomedical,  Inc., Chart Industries, and ATLANTA BIOLOGICALS

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biopreservation-market-6407

Hemangioblastoma Market to Witness Widespread Expansion During 2020 to 2023

 Market Scenario

The global hemangioblastoma market is expected to grow at the rate of 6.1% during the forecast period (2018–2023)

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6404

Segmentation

The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.

On the basis of tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram.

The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into Conformal radiotherapy, Intensity-modulated radiotherapy (IMRT), Stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hemangioblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hemangioblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The hemangioblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemangioblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global hemangioblastoma market owing to the adoption of highly advanced technology, the presence of a well-established healthcare system, rising prevalence of cancer, and increasing healthcare expenditure. According to the National cancer institute, in 2016, 15.5 million cancer cases were found in united states, and it is expected to reach 20.3 million by 2016. Also, the expenditure on cancer care in 2017 was 147.3 billion.

The European market is expected to be the second-largest hemangioblastoma market share. The market growth in this region can be attributed to government funding and support of the healthcare sector and increasing cancer cases in the region. According to the European Commission, in 2016, The European nations (EU28), total expenditure of general governments on ‘healthcare’ amounted to 7.1 % of GDP and it was around USD1000 billion.

Asia-Pacific is expected to be the fastest-growing hemangioblastoma market during the forecast period owing to the increasing prevalence of chronic diseases, government support, rising investments in healthcare and presence of huge population. According to the World Economic Forum, in 2017, more than 55% of deaths occurred due to chronic and non-communicable diseases, which is more than 8 million and out of this one-third, people were below 60years.

The market in the Middle East & Africa is expected to account for the smallest share of the global hemangioblastoma market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/hemangioblastoma-market-6404